Sitneprotafib

Sitneprotafib (JAB-3312) is a small-molecule drug developed by Allist Pharmaceuticals. The sponsor describes its target as SHP2, which OnCo does not yet have a target page for. The sponsor states: JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC. ClinicalTrials.gov describes the intervention as: JAB-3312 administered orally as a tablet or capsule. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06416410 (JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation), in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The largest, NCT06416410, plans to enrol 392 participants with primary completion expected 2029-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.